×
About 86,795 results

ALLMedicine™ Atrial Fibrillation Center

Research & Reviews  26,371 results

Pulmonary vein size is associated with reconnection following cryoballoon ablation of a...
https://doi.org/10.1007/s10840-022-01330-w
Journal of Interventional Cardiac Electrophysiology : an ... Mugnai G, Cecchini F et. al.

Aug 6th, 2022 - The second-generation cryoballoon (CB) has proven to be a highly effective ablative strategy in patients with symptomatic atrial fibrillation (AF). This study sought to investigate the anatomical characteristics of pulmonary veins (PVs) and the re...

Impact of atrioventricular junction ablation and CRT-D on long-term mortality in patien...
https://doi.org/10.1111/jce.15645
Journal of Cardiovascular Electrophysiology; Palmisano P, Ziacchi M et. al.

Aug 6th, 2022 - In patients with symptomatic permanent atrial fibrillation (PEAF) and narrow QRS, atrio-ventricular junction ablation (AVJA) plus cardiac resynchronization therapy (CRT) is superior to medical therapy in reducing heart failure (HF) hospitalization...

Prognostic model for atrial fibrillation after cardiac surgery: a UK cohort study.
https://doi.org/10.1007/s00392-022-02068-1
Clinical Research in Cardiology : Official Journal of The... Chung SC, O'Brien B et. al.

Aug 6th, 2022 - To develop a validated clinical prognostic model to determine the risk of atrial fibrillation after cardiac surgery as part of the PARADISE project (NIHR131227). Prospective cohort study with linked electronic health records from a cohort of 5.6 m...

Association of longitudinal left atrial strain with mortality after tricuspid valve sur...
https://doi.org/10.1002/ehf2.14057
ESC Heart Failure; Seo JH, Park I et. al.

Aug 6th, 2022 - Tricuspid valve (TV) surgery for functional tricuspid regurgitation (TR) is becoming more common, but the associated mortality remains high. Therefore, we evaluated the clinical and echocardiographic parameters associated with all-cause mortality ...

Trends, Predictors, and Outcomes of 30-Day Readmission With Heart Failure After Transca...
https://doi.org/10.1161/JAHA.121.024890
Journal of the American Heart Association; Zahid S, Din MTU et. al.

Aug 6th, 2022 - BACKGROUND Data on trends, predictors, and outcomes of heart failure (HF) readmissions after transcatheter aortic valve replacement (TAVR) remain limited. Moreover, the relationship between hospital TAVR discharge volume and HF readmission outcome...

see more →

Guidelines  50 results

Heart Rhythm Society Atrial Fibrillation Centers of Excellence Study: A survey analysis...
https://doi.org/10.1016/j.hrthm.2022.02.022
Heart Rhythm; Sandhu RK, Seiler A et. al.

Apr 17th, 2022 - An integrated, coordinated, and patient-centered approach to atrial fibrillation (AF) care delivery may improve outcomes and reduce cost. The purpose of this study was to gain a better understanding from key stakeholder groups on current practices...

Screening for Atrial Fibrillation: US Preventive Services Task Force Recommendation Sta...
https://doi.org/10.1001/jama.2021.23732
JAMA , Davidson KW et. al.

Jan 26th, 2022 - Atrial fibrillation (AF) is the most common cardiac arrhythmia. The prevalence of AF increases with age, from less than 0.2% in adults younger than 55 years to about 10% in those 85 years or older, with a higher prevalence in men than in women. It...

USPSTF Maintains AFib Screening Recommendation
https://www.ajmc.com/view/uspstf-maintains-afib-screening-recommendation
AJMC Shaw ML.

Jan 25th, 2022 - The US Preventive Services Task Force (USPSTF) had announced an update to its 2018 recommendation on screening for atrial fibrillation (AFib) for older adults. Despite an extensive review of evidence and new clinical trials,1 the US Preventive ...

2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on St...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763451
Thrombosis and Haemostasis; Chao TF, Joung B et. al.

Nov 14th, 2021 - The consensus of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation (AF) has been published in 2017 which provided useful clinical guidance for cardiologists, neurologists, geriatricians, and general practiti...

Endoscopy in patients on antiplatelet or anticoagulant therapy: British Society of Gast...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8355884
Gut Veitch AM, Radaelli F et. al.

Aug 8th, 2021 - This is a collaboration between the British Society of Gastroenterology (BSG) and the European Society of Gastrointestinal Endoscopy (ESGE), and is a scheduled update of their 2016 guideline on endoscopy in patients on antiplatelet or anticoagulan...

see more →

Drugs  686 results see all →

Clinicaltrials.gov  2,964 results

A Novel Healthcare Information Technology Tool to Improve Care in Patients With Atrial Fibrillation
https://clinicaltrials.gov/ct2/show/NCT02623517

Aug 5th, 2022 - This study is a prospective, observational study designed to evaluate the use of the Geneva Healthcare Patient Population Management platform to detect AF (atrial fibrillation) in patients with CIEDs (cardiovascular implantable electronic devices)...

Posterior Wall And Left Atrial Appendage Empiric Electrical Isolation for Non-Paroxysmal Atrial Fibrillation
https://clinicaltrials.gov/ct2/show/NCT04216667

Aug 5th, 2022 - The Posterior Wall and/or Left Atrial Appendage Empiric Electrical Isolation for Non-Paroxysmal Atrial Fibrillation (The PLEA Trial) is a prospective multicenter randomized controlled study that has the overall goal of establishing the efficacy an...

Evaluation of Decreased Usage of Betablockers After Myocardial Infarction in the SWEDEHEART Registry (REDUCE-SWEDEHEART)
https://clinicaltrials.gov/ct2/show/NCT03278509

Aug 5th, 2022 - REDUCE-SWEDEHEART is designed as a registry-based, randomized, parallel, open-label, multicenter trial. Patients, day 1-7 after myocardial infarction, who have undergone a coronary angiography and with preserved left ventricular systolic ejection ...

ReVeRA-201: Etripamil in Atrial Fibrillation, Phase 2
https://clinicaltrials.gov/ct2/show/NCT04467905

Aug 5th, 2022 - This is a multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of etripamil Nasal Spray in patients with atrial fibrillation (AF). This study includes Screening, the Treatment Period and Follow-up procedures. Ea...

BERRY- a Study of Sambucol ® in the Treatment, and Reduction of Symptoms in Participants With Coronavirus 19
https://clinicaltrials.gov/ct2/show/NCT05489770

Aug 5th, 2022 - The outbreak of the new coronavirus SARS-CoV-2 (COVID-19) in China has rapidly progressed to pandemic status of global importance. The current lack of a proven anti-viral that is effective has meant the current management of severe respiratory cor...

see more →

News  4,614 results

CV Admissions on the Rise in Americans With Cancer
https://www.medscape.com/viewarticle/978761

Aug 5th, 2022 - Although cardiovascular disease (CVD) is known to often strike the mortal blow in patients with cancer, a national analysis puts in stark relief the burden of CV-related hospitalizations in this vulnerable population. Results show that between 200...

Targeted Therapy for Kidney Cancer Linked to Higher Cardiac Risk
https://www.medscape.com/viewarticle/978519

Aug 3rd, 2022 - New research offers more evidence linking targeted therapies for patients with advanced renal cell carcinoma to higher risks for major adverse cardiovascular events. Patients on targeted therapy were more likely to develop conditions such as heart...

Commentary: Diabetes Drug Comparisons, August 2022
https://www.mdedge.com/type-2-diabetes-icymi/article/256774/diabetes/commentary-diabetes-drug-comparisons-august-2022

Aug 2nd, 2022 - Ronald M. Goldenberg, MD, FRCPC, FACE Meta-analyses of s odium-glucose cotransporter 2 inhibitor (SGLT2i) outcome trials have shown reductions in all-cause and cardiovascular mortality, but dipeptidyl peptidase 4 inhibitors (DPP4i) have been neutr.

SGLT2i vs GLP-1RA or DPP4i lowers the risk for new-onset AF in T2D
https://www.mdedge.com/type-2-diabetes-icymi/article/256644/diabetes/sglt2i-vs-glp-1ra-or-dpp4i-lowers-risk-new-onset-af

Jul 31st, 2022 - Key clinical point: Sodium-glucose cotransporter-2 inhibitor (SGLT2i) use was associated with a lower risk for new-onset atrial fibrillation (AF) in patients with type 2 diabetes (T2D) compared with the use of either glucagon-like peptide-1 recept.

Exceeding Exercise Guidelines Boosts Survival, to a Point
https://www.medscape.com/viewarticle/977998

Jul 26th, 2022 - A new study suggests that going beyond current guidance on moderate and vigorous physical activity levels may add years to one's life. Americans are advised to do a minimum of 150 to 300 minutes a week of moderate exercise or 75 to 150 minutes a w...

see more →

Patient Education  33 results see all →